Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1126/science.abf1611 http://scihub22266oqcxt.onion/10.1126/science.abf1611 33602867!8099175!33602867     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Science 2021 ; 371 (6536): 1374-1378 Nephropedia Template TP {{tp|p=33602867|t=2021. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model |pdf=|usr=}}{{33602867}} gab.com Text SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model JO: Science http://www.kidney.de/pget.php?&tw=1&pmid=33602867 #FOAvip The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M(pro) inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M(pro) activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M(pro) in complex with MI-23, one of the most potent compounds, revealed its interaction mode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment with MI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats. Twit Text FOAVip SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model ????Science http://www.kidney.de/pget.php?&tw=1&pmid=33602867 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33602867 #FOAvip English Wikipedia <ref>{{Cite pmid|33602867}}</ref> SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model #MMPMID33602867 Qiao J; Li YS; Zeng R; Liu FL; Luo RH; Huang C; Wang YF; Zhang J; Quan B; Shen C; Mao X; Liu X; Sun W; Yang W; Ni X; Wang K; Xu L; Duan ZL; Zou QC; Zhang HL; Qu W; Long YH; Li MH; Yang RC; Liu X; You J; Zhou Y; Yao R; Li WP; Liu JM; Chen P; Liu Y; Lin GF; Yang X; Zou J; Li L; Hu Y; Lu GW; Li WM; Wei YQ; Zheng YT; Lei J; Yang S Science 2021[Mar]; 371 (6536): 1374-1378 PMID33602867show ga The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continually poses serious threats to global public health. The main protease (M(pro)) of SARS-CoV-2 plays a central role in viral replication. We designed and synthesized 32 new bicycloproline-containing M(pro) inhibitors derived from either boceprevir or telaprevir, both of which are approved antivirals. All compounds inhibited SARS-CoV-2 M(pro) activity in vitro, with 50% inhibitory concentration values ranging from 7.6 to 748.5 nM. The cocrystal structure of M(pro) in complex with MI-23, one of the most potent compounds, revealed its interaction mode. Two compounds (MI-09 and MI-30) showed excellent antiviral activity in cell-based assays. In a transgenic mouse model of SARS-CoV-2 infection, oral or intraperitoneal treatment with MI-09 or MI-30 significantly reduced lung viral loads and lung lesions. Both also displayed good pharmacokinetic properties and safety in rats. |*COVID-19 Drug Treatment[MESH] |Animals[MESH] |Antiviral Agents/chemistry/*pharmacology/therapeutic use[MESH] |COVID-19/pathology/virology[MESH] |Cell Line[MESH] |Cell Survival/drug effects[MESH] |Chemokine CXCL10/metabolism[MESH] |Coronavirus 3C Proteases/*antagonists & inhibitors[MESH] |Disease Models, Animal[MESH] |Drug Design[MESH] |Humans[MESH] |Interferon-beta/metabolism[MESH] |Lung/immunology/pathology/virology[MESH] |Mice[MESH] |Mice, Transgenic[MESH] |Oligopeptides[MESH] |Proline/analogs & derivatives[MESH] |Protease Inhibitors/chemistry/*pharmacology/therapeutic use/toxicity[MESH] |Rats[MESH] |Rats, Sprague-Dawley[MESH] |Viral Load/drug effects[MESH]SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic m(epmc).pdf DeepDyve Pubget Overpricing